Incyte (INCY) Net Equity Issued and Repurchased (2010 - 2011)
Incyte's (INCY) quarterly Net Equity Issued and Repurchased came in at $1.1 million in Q3 2011, down 68.28% YoY from $3.4 million in Q3 2010, and down 91.42% on a QoQ basis from $12.5 million in Q2 2011.
Powered by 
Analysis
Incyte (INCY) Net Equity Issued and Repurchased (2010 - 2011) Analysis & Trends
Incyte (INCY) has 2 years of Net Equity Issued and Repurchased data on file, last reported at $1.1 million in Q3 2011.
- Quarterly Net Equity Issued and Repurchased fell 68.28% year-over-year to $1.1 million in Q3 2011, while the trailing twelve-month figure through Dec 2017 was $17.7 million (changed N/A YoY) and the FY2017 annual result came in at $649.4 million, changed N/A from the prior year.
- Net Equity Issued and Repurchased slipped to $1.1 million in Q3 2011, from $12.5 million in the prior quarter.
- In the past five years, Net Equity Issued and Repurchased ranged from a high of $12.5 million in Q2 2011 to a low of $1.1 million in Q3 2011.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 141.90 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Incyte | 25.44 Bn | 20.91 Bn | 1.57 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2011 | 1.07 Mn |
| Jun 30, 2011 | 12.51 Mn |
| Mar 31, 2011 | 4.13 Mn |
| Sep 30, 2010 | 3.38 Mn |
| Jun 30, 2010 | 2.43 Mn |
| Mar 31, 2010 | 4.23 Mn |